MedTrace Logo

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

NCT00999401 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2021-12-22

No results posted yet for this study

Summary

A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.

Conditions

Interventions

DRUG

sapacitabine and seliciclib

sequential or concomitant administration of sapacitabine and seliciclib

Sponsors & Collaborators

  • Cyclacel Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Geoffrey Shapiro, M.D. · Dana-Farber Cancer Institute

  • Sara Tolaney, M.D. · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2019-07-16
Completion
2019-08-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999401 on ClinicalTrials.gov